A ten-year study of Retinoblastoma in Uganda: An approach to improving outcome with limited resources

Abstract

Background: Survival of children with cancer in resource-limited regions is very poor compared to better-resourced regions. Retinoblastoma (RB) is a childhood cancer that is commonly reported in many regions of Africa. RB may be safely and effectively treated by non-specialists, which could facilitate more wide spread availability of treatment in under-resourced areas. Methods: A ten-year consecutive series of children with RB treated at Ruharo Eye Centre between December 2009 and November 2019 was prospectively followed up. Chemo-reduction followed by surgery is the standard approach to therapy. Costs of therapy and also of travel and food are borne by the program which is unaffordable to most families and necessitates donors. Survival by stage of RB and number of eyes affected was described using Kaplan-Meier plots. Visual acuity was assessed for all children with bilateral disease and the retention of sight during follow-up assessed. Results: Among 665 children with RB, 18.2% (121children) presented with metastatic (Stage4) RB with only two of these children surviving>24 months. Five-year survival was 60.2% among all children with RB rising to 93.3% and 87.2% for children with unilateral and bilateral Stage1 disease, respectively. Among 184 children with bilateral disease, 130 (70.7%) retained some level of sight following primary treatment with 91 of those (49.5% of all bilateral children) retaining vision up to their death or to the end of follow-up. Conclusion: Many children in Uganda present with advanced RB and curative treatment is not possible in this setting. Children diagnosed and treated early have good prospects of survival. Retention of sight among many bilaterally affected children is achievable, facilitating access to normal education. Therefore, the strategic priorities for improving survival are changing community perceptions so that children with eye problems are brought without delay, and widening access to modern treatment by using gene real health workers with standard drugs, backed by financial, social and peer support